论文部分内容阅读
用免疫扩散法对１７４例（２２１例次）各型呼吸功能不全（ＲＩ）患者进行血浆纤连蛋白（ＰＦｎ）测定。结果２２１例次中ＰＦｎ（ｍｇ／Ｌ）８５例次ＲＩ为２５３．１２±６７．００，２７例次１型呼吸衰竭（ＲＦＩ）为１４１．９７±７０．８４，８２例次ＲＦⅡ为１８０．４８±４９．９６，２７例次医源性ＲＦ（ＩＲＦ）为２６３．４９±７０．０５，显著低于正常对照组（２９２．４±４３．１１，Ｐ＜０．００１及０．０５）。ＲＦⅠ、Ⅱ和ＩＲＦ的ｐＦｎ水平与ＰａＯ＿２呈正相关，ＲＦⅡ的水平侧与ＰａＣＯ＿２呈负相关。３４例ＲＦ治疗前（１４７．８０±６１．５９）显著低于治疗后１５天（２１４．６２±５６．１２，Ｐ＜０．００１）。３３例ＲＦ的ＰＦｎ＜１５０ｍｇ／Ｌ：并发多器官功能衰竭１８例，死亡３例（２例低于１００ｍｇ／Ｌ）。作者认为，ＰＦｎ含量可作为早期诊断ＲＦ、监测ＲＦ病情及预后的一项指标。
174 cases (221 cases) of respiratory insufficiency (RI) were measured by immunodiffusion method for determination of plasma fibronectin (PFn). Results 221 cases of PFn (mg / L) 85 cases of RI was 253.12 ± 67.00, 27 cases of type 1 respiratory failure (RFI) was 141.97 ± 70.84, 82 cases of RF Ⅱ was 180. 48 ± 49.96,27 cases of iatrogenic RF (IRF) was 263.49 ± 70.05, significantly lower than the normal control group (292.4 ± 43.11, P <0.001 and 0.05) . The levels of pFn in RFⅠ, Ⅱand IRF were positively correlated with PaO_2, while the level of RFⅡwas negatively correlated with PaCO_2. 34 cases RF before treatment (147.80 ± 61.59) was significantly lower than 15 days after treatment (214.62 ± 56.12, P <0.001). 33 cases of RF PFn <150mg / L: complicated by multiple organ failure in 18 cases, 3 patients died (2 cases less than 100mg / L). The authors believe that, PFn content can be used as an early diagnosis of RF, RF status and prognosis of an indicator.